OXFORD - If Geron Corp. was the out-of-town suitor that won the hand of Roslin Bio-Med Ltd. and its nuclear transfer cloning technology, PPL Therapeutics plc was the local boy that was passed over.

As a result, PPL (LSE:PTH, Roslin, U.K.) is left with a fairly narrow license to technology for the production of therapeutic proteins in milk. But the company hasn't given up hope that it may be able to obtain a license from GERN to its other area of interest in xenotransplant.